Dr. Husein K. Salem, BSc PhD is a molecular biologist, with a PhD in Molecular Medicine (specifically gene and cell therapy), who went on to hold a Postdoctoral Fellowship at Imperial College London, Department of Medicine.
His research in gene and cell therapies was particularly focused on the use of stem cells in the treatment of cardiovascular and coronary diseases (heart attacks, strokes) as well as neurological conditions such as motor-neurone diseases (including amyloid lateral sclerosis), Huntington’s, Parkinson’s and Alzheimer’s.
Husein has received major academic accolades, and has presented to the British Cardiac Society, the American Society of Gene Therapy and the British Society of Gene Therapy. Furthermore, he has held a Medical Research Council Scholarship as well as a European Research Council Fellowship. Husein currently holds the role of UK Ambassador for the Cell Therapy Foundation (CTF).
He is also a published scientific author with papers appearing in leading international medical journals (see below).
Having excelled within his scientific field, Husein was invited to join the Scientific Advisory Board of one of the UK’s private cord blood banks. He has since founded his own private stem cell bank, Precious Cells International, which is the first bank in the UK licensed to collect and store stem cells from five sources in the body.
Husein says, “I have spent the best part of my career working in some of the UK’s most elite academic centres, researching how translational medicine using cellular therapy can be used to treat a range of diseases. I passionately believe that stem cells and regenerative medicine will successfully be used to treat devastating diseases in the very near future.”
As a subject-matter expert, Dr. Husein K. Salem is available for opinion and comment on stem cell research, translational medicine, cell and gene therapies and related topics.
For further press information contact:
List of Dr. Salem’s published papers:
H.K.Salem, C.Thiemermann. Mesenchymal Stromal Cells — Current understanding and clinical status. Stem Cells 2010 Mar 31; 28(3):585-96.
Ranjzad P, Salem HK, Kingston PA. Adenovirus-mediated gene transfer of fibromodulin inhibits neointimal hyperplasia in an organ culture model of human saphenous vein graft disease. Gene Ther. 2009 Sep; 16(9):1154-62. Epub 2009 May 28.
K.Takahashi, S.Fukushima, K.Yamahara, K.Yashiro, Y.Shintani, S.R.Coppen, H.K.Salem, S.W.Brouilette, M.Yacoub, K.Suzuki. Modulated inflammation by injection of high mobility group box 1 recovers post-infarction. Circulation 2008 Sep 30; 118: S106-14.
S.R.Coppen, S.Fukushima, Y.Shintani, K.Takahashi, A.Varela-Carver, H.K.Salem, K.Yashiro, M.H.Yacoub, K.Suzuki. A factor underlying arrhythmogenicity after cell therapy to the heart: global down-regulation of connexin43 in the host myocardium following skeletal myoblast transplantation. Circulation 2008 Sep 30; 118: S138-4.
A.K.Salem, M.K.Salem, H.K.Salem, S.Tapya. New technologies and therapies for cancer. Encyclopedia of Cancer and Society. Sage Publications 2007.
Salem HK, Appleby CE, Ranzjad P, Driessen A, Heagerty AM, Kingston PA. Beta-adrenoceptor blockade markedly attenuates transgene expression from cytomegalovirus promoters within the cardiovascular system. Arterioscler Thromb Vasc Biol October 2006; 26:2267 — 227.
Salem HK, Kingston PA, Heagerty AM. Beta-blockers restrict maximum levels of transgene expression elicited by CMV promoters in vascular smooth muscle cells. Molecular Therapy;9:S152-S152 395 Suppl. 1 MAY 2004.
Notes to Editors
Dr Husein K. Salem was born in Leicester where he went to school at Wyggeston Queen Elizabeth I College. He graduated from the University of Manchester, Institute of Science & Technology, with Honours and remained at the University to study for his Doctoral Degree. He now lives in London with his wife, Dr. Nasreen Najefi, a dentist, and their two children. Husein is also a keen footballer who plays for London DB FC.
Precious Cells BioBank, a London based Medtech Company founded in 2009, has established an international reputation in the commercialisation and innovation of Stem Cells, cord blood and Regenerative Medicine. Cord blood is extensively being investigated as a basic science therapeutic to create biological products, including regenerative medicines and cellular therapies. Regenerative medicine is a broad definition for innovative medical therapies that will enable the body to repair, replace, restore and regenerate damaged or diseased cells, tissues and organs. Regenerative therapies that are in clinical trials today may enable repair of damaged heart muscle following heart attacks, replacement of skin for burns victims, restoration of movement after spinal cord injury, regeneration of pancreatic tissue for insulin production in diabetics and provide new treatments for Parkinson’s and Alzheimer’s diseases, to name just a few applications. The company continues to monitor research and advances in regenerative medicine. The Company is headquartered at Biobank Center of Excellence, Brunel Science Park, where it has built a dedicated, clean-room stem cell processing laboratory.
